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Mammalian prions are hypothesized to be fibrillar or amyloid forms of
prion protein (PrP), but structures observed to date have not been defini-
tively correlated with infectivity and the three-dimensional structure of
infectious prions has remained obscure. Recently, we developed novel
methods to obtain exceptionally pure preparations of prions from mouse
brain and showed that pathogenic PrP in these high-titre preparations is
assembled into rod-like assemblies. Here, we have used precise cell
culture-based prion infectivity assays to define the physical relationship
between the PrP rods and prion infectivity and have used electron tomogra-
phy to define their architecture. We show that infectious PrP rods isolated
from multiple prion strains have a common hierarchical assembly compris-
ing twisted pairs of short fibres with repeating substructure. The architecture
of the PrP rods provides a new structural basis for understanding prion
infectivity and can explain the inability to systematically generate high-titre
synthetic prions from recombinant PrP.1. Introduction
Prions are unique pathogens, devoid of significant coding nucleic acid, which
cause lethal neurodegenerative diseases in mammals, including scrapie in
sheep and goats, bovine spongiform encephalopathy (BSE) in cattle and
Creutzfeldt–Jakob disease (CJD) in humans [1–3]. They are hypothesized to
be fibrillar or amyloid forms of prion protein (PrP), which self-propagate by
means of seeded protein polymerization [1,2]. It is increasingly recognized
that similar seeding processes may be involved in Alzheimer’s disease and
other degenerative conditions [4].
To date the three-dimensional structure of infectious prions and how this
differs from non-infectious amyloid fibrils remains unknown. Prion-infected
brain contains infectious PrP assemblies of variable size that can be fractionated
[5–9], but the production of highly homogeneous material of demonstrable
high specific infectivity to allow direct correlation of particle structure with
infectivity has proved extremely challenging. Moreover, the knowledge that
partially purified prions can be fragmented in vitro to generate smaller oligo-
meric PrP assemblies of high specific prion infectivity [6] has not yet
facilitated the provision of material suitable for high-resolution structural
studies. Recently, however, we developed new methods [10] to obtain excep-
tionally pure preparations of intact prions from mouse brain, and showed
that pathogenic PrP in these preparations is assembled into rod-like assemblies
(PrP rods) akin to those described by Prusiner and colleagues [1,11].
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2Importantly, the PrP rods that we prepare contain disease-
related PrP at greater than 99% protein purity [10], and
these are therefore devoid of detectable protein contaminants
which might confound structural studies. The fact that these
preparations have very high titres of infectious prions which
faithfully transmit prion strain-specific phenotypes when
inoculated into mice [10] makes them eminently suitable for
detailed study. Here, we have used the precision of cell cul-
ture prion infectivity assays [10,12–16] to define the
physical relationship between the PrP rods and prion infec-
tivity and have used electron tomography to define their
architecture.
We show that PrP rods isolated ex vivo from multiple
prion strains are intrinsically infectious. Furthermore, we
show that the PrP rods are formed in infected brain and are
not, as previously thought, an artefact of extraction protocols
involving proteases and detergents [17]. They have a
common hierarchical assembly comprising twisted pairs of
short fibres with repeating substructure. Such paired fibre
assembly is markedly different to the long single fibre organ-
ization of non-infectious PrP fibrils generated from
recombinant PrP. This novel architecture now provides a
new basis for understanding the distinctive properties of
prions compared to non-infectious amyloid structures.2. Results
2.1. Prion protein rods are intrinsically associated
with prion infectivity
Central to understanding prion infectivity is the ability to
determine the structure of assemblies unequivocally known
to represent the infectious state and to correlate morphologies
with infectivity [1,2,18,19]. Although electron microscopy
(EM) has been used for more than 30 years to investigate pur-
ified prion preparations, none of the observed EM structures
to date have been definitively correlated with prion infectiv-
ity. Indeed, it is currently unknown whether prions adhere
efficiently to the support film of EM grids. To establish that
the PrP structures we observe by EM are directly associated
with prion infectivity, we applied aliquots of highly purified
mouse prions [10] (RML strain; figure 1a,b) to individual
carbon-coated gold EM grids and measured surface bound
infectivity in cell culture using a novel method that we
term the Scrapie Cell Grid Assay (SCGA; figure 1c). We
found that purified prions bind avidly to carbon-coated EM
grids (less than 5% of the applied infectivity was removed
from dried grids by successive water washes; electronic sup-
plementary material, table S1), and remarkably the SCGA
reported prion infectivity titre with an efficiency equivalent
to, or better than, measuring prions in solution (electronic
supplementary material, table S2). We conclude that prions
bind to EM grids with near 100% efficiency and that their
infectivity is not significantly altered once bound to the
grid surface. These findings are reminiscent of the highly effi-
cient binding of prions to stainless steel wires that has been
documented previously [20–22]. Importantly, on EM grids
on which the entire sample had been allowed to dry, PrP
rods remain the only visible protein structures (figure 1d ).
To exclude the possibility that smaller PrP assemblies [6]
(that are either too small or sparsely populated to be
observed by EM) carried the infectivity, we fractionated thepurified prion samples by filtration and similarly analysed
fractions by EM and in cell culture. We found that less than
4% of the starting infectivity and PrP was recovered in
filtrates from 0.1 mm pore-sized membranes. If smaller PrP
assemblies of the size and specific infectivity reported by
Caughey and colleagues [6] were present in our PrP rod prep-
arations we would have expected these to have traversed the
0.1 mm-sized pores of the filter. However, we found no
evidence for these in our preparations. When examined by
EM the filtrates showed only occasional short PrP rods with
morphology congruent with those retained by the filter. Col-
lectively, these findings firmly establish a tight physical
association between prion infectivity and the PrP rods
observed by EM.
2.2. Prion protein rods are present in infected brain
The PrP rods in our purified mouse prion preparations have a
gross morphology that closely resembles the prion rods seen
in preparations of purified hamster prions isolated by Prusi-
ner and colleagues [1,11]. These were considered artefactual
and attributed to in vitro formation during purification of
prions from brain by a process requiring both detergent
and limited proteolysis of pathogenic PrP (PrPSc) [17]. We
sought evidence for such an in vitro assembly process by
directly applying detergent solution (2% (w/v) sarkosyl in
D-PBS) to crude 10% (w/v) RML brain homogenate and
visualizing the samples by EM. In the absence of detergent,
the heterogeneity of brain homogenate obscures visualization
of PrP rods. However, exposure of brain homogenate to
detergent for as little as 10 min readily facilitated visualiza-
tion of PrP rods (figure 2a,b) with dimensions similar to
those seen in highly purified samples. Importantly, the
number and morphology of the PrP rods appeared to be
the same regardless of the time of exposure of brain
homogenate to detergent (from 10 to more than 60 min) or
if brain homogenate was diluted 100-fold into detergent
solutions in such reactions (figure 2b). Although EM is not
a quantitative method (which precludes formal statistical
analyses of PrP rod numbers), such apparent lack of time
or protein concentration dependence does not support an in
vitro assembly process as the source of the PrP rods unless
this is extremely efficient and occurring on very short time
scales (less than 10 min). To investigate this, we included a
high concentration (200 mg ml21) of proteinase K (PK) in
the detergent solution and repeated the time course exper-
iments. Despite the protease being present from the
moment detergent and brain homogenate were mixed, we
saw no detectable impact on our ability to observe the rods
or any noticeable change in their morphology (compare
figure 2c with figure 2a,b,d–h). Importantly, at this concen-
tration, PK is sufficiently active to destroy PrPC in normal
mouse brain homogenate within 5 min [13]. Thus, if an
assembly process were occurring on very short time scales,
it would have to involve virtually no structural rearrange-
ment of PrP conformation on addition of protein monomers
to the rod, as any accessible scissile bonds should be targeted
by the protease. Our findings also do not support detergent-
facilitated assembly of the rods from smaller, protease-
resistant, beta-sheet-rich PrP multimers. Such precursors
were not seen by EM in our immunogold labelling exper-
iments and again the kinetics of any assembly reaction
would be critically dependent upon protein concentration.
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Figure 1. Ex vivo PrP rods are physically associated with prion infectivity. (a) Silver-stained 16% SDS-PAGE gel of RML prion preparations purified with (þ) or
without (– ) proteinase K (PK) digestion compared to equivalent fractions from uninfected normal CD1 mouse brain. (b) EM image of an RML prion preparation
purified without PK digestion. PrP rods (shown here immunogold-labelled with an anti-PrP monoclonal antibody) are the only visible protein structures. (c) Sche-
matic of novel cell culture methods (Scrapie Cell Grid Assay, SCGA) used to measure prion infectivity bound to the surface of EM grids. (d ) EM image of PrP rods
(RML strain) observed when purified prion samples are dried onto the microscope grid without washing with water. Visible background objects are non-protein
buffer artefacts (that include detergent micelles). Purified prions bind tightly to grids with less than 5% of the applied infectivity removed from dried grids by
successive water washes; see the electronic supplementary material, table S1. The SCGA reported prion infectivity titre with an efficiency equivalent to, or better
than, measuring prions in solution, see the electronic supplementary material, table S2. (e) EM image of PrP rods (RML prion strain) isolated from brain without the
use of detergent. Scale bars, 50 nm.
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Figure 2. Visualization of PrP rods in crude RML brain homogenate. In total, 10% (w/v) RML brain homogenate was diluted twofold or 100-fold into 2% (w/v)
sarkosyl (either lacking or containing 200 mg ml21 PK) and incubated for various time periods (between 2.5 and 60 min). At the end of the incubation period,
samples were centrifuged at 16 100g for 5 min. The supernatant was discarded and the pellets resuspended in TBS to one-third of the volume of the starting brain
homogenate and immediately applied to EM grids. PrP rods were visualized by negative stain EM and their identity confirmed by immunogold labelling using
anti-PrP monoclonal antibody SAF-32. The times reported include centrifugation time and the time taken to load EM grids. (a) RML brain homogenate diluted
twofold in sarkosyl for 10 min. (b) RML brain homogenate diluted 100-fold in sarkosyl for 10 min. (c) RML brain homogenate diluted twofold in sarkosyl containing
200 mg ml21 PK for 20 min. (d ) RML brain homogenate diluted twofold in sarkosyl for 20 min (no PK). (e) Immunogold-labelled PrP rods in sarkosyl-treated RML
brain homogenate. ( f ) Immunogold-labelled PrP rods in purified ME7 prion samples. (g) Immunogold-labelled PrP rods in purified RML prion samples. (h) A control
experiment showing the specificity of the immunogold labelling method. Labelling of purified PrP rods (RML strain) is abolished when a 100-fold molar excess of
recombinant mouse PrP is included with the SAF-32 primary antibody. (i) PrP rod isolated from RML brain homogenate without detergent. Scale bars, 100 nm.
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4On the basis of these data, we considered that detergent
serves to facilitate the observation of pre-existing PrP rods
in brain homogenate rather than to catalyse their formation.
Further experiments strongly supported this idea. We
were able to isolate PrP rods from brain without using deter-
gent (figures 1e and 2i) and found that they have a similar
morphology to those present in highly purified samples. Con-
sistent with this finding, we also found that the thermal and
chemical inactivation profiles of prion infectivity in brain
homogenate and purified prion preparations were closely
similar (figure 3a–c). PrP rods (figure 3d,e) were no longer
detectable by EM in samples in which infectivity had been
denatured, either in purified prion samples (figure 3f ) or in
brain homogenate. Heat denaturation of prion infectivity at
1008C (which typically reduces prion titre by more than
100-fold when measured by rodent bioassay [23,24]) could
be correlated with a conformational change of PrP within
the rods as evidenced by increased sensitivity of the protein
to digestion with PK (electronic supplementary material,
figure S1). The similarity of the thermal and chemicalinactivation profiles of prion infectivity in brain homogenate
and purified samples clearly suggests the destruction of the
same infectious structures in both preparations. Based upon
our collective data, we conclude that the PrP rods observed
in our purified prion samples originate from the brain and
are not assembled in vitro. Demonstration that PrP rods are
intrinsically infectious and originate in vivo firmly establishes
the importance of understanding their structure.2.3. Aggregates of prion protein rods behave as discrete
infectious particles
All preparations of purified prions have a large ratio of PrP
molecules per infectious unit in rodent bioassay [6,10,11,25]
and in cell culture [10]. Differences in the length of infectious
PrP rods (in which the propagating ends of the rod can be
considered the infectious entity [2,26,27]) can readily accom-
modate variance in specific prion infectivity with respect to
PrP monomers. Since the rods aggregate with non-uniform
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Figure 3. Heat and chemical inactivation of prions. Replicate aliquots of purified RML prions or RML brain homogenate were heated at different temperatures for
defined times or incubated with different concentrations of guanidine hydrochloride (GuHCl) for 30 min and the infectivity in the samples measured using the
Scrapie Cell Assay and expressed as a percentage (mean+ s.e.m., n ¼ 3) of that present in the starting preparation. Samples were also analysed by immuno-
blotting (see the electronic supplementary material, figure S1). (a,b) Thermal inactivation profiles, purified prions (a), brain homogenate (b). (c) GuHCl inactivation.
(d– f ) EM images of purified prions incubated for 30 min at 258C (d ), 508C (e) or 1008C ( f ), showing thermal denaturation of PrP rods. PrP rods were more
sensitive to digestion with PK after heat denaturation of prion infectivity at 1008C compared to 258C (see the electronic supplementary material, figure S1).
Scale bars, main panels 500 nm, magnified insets 100 nm.
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5distributions on the grid, their concentration could not be
estimated from the images. Nevertheless, the dimensions of
the PrP rods could be readily estimated, as could their aggre-
gation state. The rods appeared relatively consistent in width
(approx. 21 nm) and although their length varied (50–
350 nm), most were between 100 and 200 nm long (electronic
supplementary material, table S3). The greatest variation that
we observed was the number of PrP rods per aggregate. Indi-
vidual aggregates could contain from five to several hundred
individual PrP rods and we rarely observed PrP rods in iso-
lation. Therefore, we considered that PrP rod aggregates
might act as discrete infectious particles in cell culture. Totest this, identical aliquots of purified prions were treated to
re-distribute the PrP rods in the sample into a greater or smal-
ler number of aggregates, after which infectivity was
measured in the Scrapie Cell Assay and the samples visual-
ized by EM (figure 4). Findings from this experiment were
unequivocal. Sonicated samples had a greater number of
small dispersed aggregates of PrP rods and had a higher
specific infectivity than untreated samples, whereas centri-
fuged samples had a lower number of much larger PrP rod
aggregates and lower specific infectivity (figure 4). While
sonication caused fragmentation of some of the PrP rods to
produce shorter lengths (thus increasing the number of
purified prions
sonicate centrifuge
100 000g
resuspend in
same supernatant
load on EM gridsload on EM gridsload on EM grids
192 ± 14%
infectivity
23 ± 2%
infectivity
100%
infectivity
Figure 4. Aggregates of PrP rods act as discrete infectious particles in cell culture. Replicate aliquots of purified RML prions were either sonicated or centrifuged to
alter the aggregation state of PrP rods and compared to untreated samples by negative stain EM. Infectivity titre of the treated samples was determined using the
Scrapie Cell Assay and expressed as a percentage of that present in the untreated sample (mean+ s.d., n ¼ 3). Sonication generates a greater number of small
dispersed aggregates of PrP rods and higher prion titre, whereas centrifugation produces a reduced number of larger sized aggregates and lower prion titre. Scale
bars, 100 nm.
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6ends) as well as altering aggregate size and number
(figure 4), centrifugation only caused alterations to aggregate
size and number. Thus, without adding to, or removing,
anything from the samples we established that changing
the number of aggregates into which the PrP rods are dis-
tributed changes the number of infectious units available to
cells at inoculation. These findings demonstrate that PrP
rods are the constituents of discrete infectious particles
whose size can be altered. The ability to alter specific prion
infectivity simply by centrifuging the sample to produce
larger aggregates of the rods indicates that such effects on
bioavailability must be considered when characterizing puri-
fied prion preparations. These data also highlight the power
of cell culture infectivity assays to gain new insight into the
physical basis of prion infectivity as the variance in the
specific infectivity that we observed in our samples
(approx. eightfold) lies within the typical error rangeassociated with measuring prion infectivity titre in rodent
bioassays (typically mean+ 0.5 log) [28].
2.4. Three-dimensional structure of prions
Having provided compelling physical evidence linking ex vivo
PrP rods with prion infectivity and showing that discrete aggre-
gates of PrP rods appear to behave as infectious particles in cell
culture, we analysed their three-dimensional structure by elec-
tron tomography of negatively stained samples. All the prions
examined showed a common structure. The rods contained a
pair of short, intertwined fibres, each with a double helical
repeating substructure, separated by a distinct gap 8–10 nm
in width (figure 5; electronic supplementary material, table
S3). The structure of this twisted assembly is difficult to discern
in EM images, which are two-dimensional density projections.
However, the twist of the paired fibrils as well as a twisted two
(b)
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(c)
(d )
repeating substructure fibre 1
fibre 2
8–10 nm gapro
d 
1
ro
d 
2
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Figure 5. Three-dimensional reconstruction by electron tomography of
prions reveals structures distinct from non-infectious recombinant PrP
fibrils. (a–d ) Sections through negative stain electron tomography recon-
structions. (a) Non-infectious recombinant PrP fibril compared with
infectious ex vivo PrP rods from (b) RML-infected CD1 mouse brain, (c)
ME7-infected C57Bl/6 mouse brain and (d ) RML-infected C57Bl/6 mouse
brain. Dimensions of the PrP rods are provided in the electronic sup-
plementary material, table S3. (e) An isosurface view of a tomographic
reconstruction (see the electronic supplementary material, movie S1) of
two individual ME7 prion rods purified from C57BL/6 mouse brain showing
each rod to be composed of two fibres twisted round one another sep-
arated by a distinct gap 8–10 nm in width. The repeating substructure is
less evident than in the density sections, after the filtering needed for
isosurface representation. Scale bars, 50 nm.
(b)
(a)
Figure 6. Ex vivo infectious PrP rods have a common building block re-
gardless of prion strain type. Common structural features are recognizable
in two-dimensional negative stain images of PrP rods isolated from
(a) RML prion-infected CD1 mouse brain and (b) Sc237 prion-infected
hamster brain (red arrows) showing paired PrP fibres with a double helical
substructure, separated by an 8–10 nm gap. Both images show a typical
view of multiple PrP rods in an aggregate (detergent micelles can be
observed in the background). Scale bar, 50 nm.
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7stranded structure within each fibril become apparent when the
three-dimensional structure of the assembly is resolved by tom-
ography (electronic supplementary material, movie S1). The
hierarchical assembly of paired fibrils into PrP rods has not
previously been described in three dimensions [6,11,17,29,30],
nor has there been a three-dimensional structural comparison
of infectious and non-infectious PrP assemblies. Our three-
dimensional analysis strongly suggests that all ex vivo
infectious PrP rods have a common building block comprising
paired fibres with a double helical substructure regardless of
prion strain type (figure 5; electronic supplementary material,
movie S1). On the basis of our tomograms, these structural fea-
tures can now be readily recognized in our two-dimensional
images of PrP rods (consistently in multiple preparations and
thousands of rods visualized) [10] (figure 6) and in earlier
images of PrP rods isolated from hamster [17] or mouse brain
[29] by others. While structural differences that distinguish
prion strains may become apparent with higher resolution
methods (such as cryo-tomography and subtomogram aver-
aging), the architecture of the PrP rods now provides a basisfor explaining the distinctive physico-chemical properties of
prions in comparison to non-infectious PrP fibrils.
PrP fibrils generated by us from recombinant PrP show no
infectivity in either cell culture or rodent bioassay, even when
assayed at high concentrations or after sonication to produce
more fibril ends (electronic supplementary material, figure S2
and table S4) [31]. In contrast to the structural complexity of
PrP rods, they have a simpler construction [32] (figure 5a).
These recombinant PrP fibrils resemble the individual fibres
present in ex vivo PrP rods, but they do not assemble to
produce intertwined paired fibres (figure 5; electronic sup-
plementary material, table S3). The recombinant fibrils have a
double helical arrangement of two protofilaments with a 60
A˚ globular repeat [32], and are very long and somewhat
wider than the individual fibres in the ex vivo PrP rods.
Recent structural modelling of non-infectious recombinant
PrP fibrils generated through prion-seeded real-time quaking-
induced conversion (RT-QuIC) reactions suggested that PrP
rods are single protofilaments [30], but this proposal is incom-
patible with the three-dimensional architecture of the PrP rods
rsob.royalsocietypublishing.org
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8that we describe here. Hierarchical assembly of PrP into a
paired fibre structure (figure 5b–e) appears to be a key feature
of infectious prions. This arrangement may contribute signifi-
cantly to the remarkable resistance of prions to degradation,
which is likely to be crucial to their natural transmissibility,
for example by dietary exposure. Whereas non-infectious
recombinant PrP fibrils have a highly exposed surface, the
paired fibres within the PrP rod may be less accessible to pro-
teases. Moreover, while recombinant PrP fibrils are composed
solely of non-glycosylated PrP, ex vivo PrP rods are composed
of defined ratios of di-, mono- and non-glycosylated PrP [10].
The characteristic 8–10 nm gap between the two fibres of
repeating structure in the rods (figure 5b–e; electronic sup-
plementary material, movie S1) suggests a possible location
for some of the N-linked glycans that may contribute to the
stability of the assembly, and as a consequence its infectivity.
Such an arrangement of the glycans may protect a significant
fraction of the protein surface and suggests a plausible steric
basis for generating the highly consistent PrP glycoform
ratios that characterize different prion strains [10,33–36].
Regarding glycan accessibility, prolonged incubation of RML
PrP rods with neuraminidase, a range of endoglycosidases or
PNGase F had no discernible effect on the morphology of the
rods when viewed by EM or on the mobility of PrP glycoforms
when viewed on immunoblots (2015, our unpublished obser-
vations). These findings suggest that the N-linked glycans
are buried within the structure of the rod, but further
experiments are required to confirm this.3. Discussion
Progress in understanding prion structure has been severely
hindered by the difficulty of isolating relatively homogeneous
prion particles from affected tissue and unequivocally correlat-
ing infectivity with composition and structure. Here, using
new and highly effective methods for prion isolation [10]
together with sensitive cell culture infectivity assays we
show that PrP rods in our preparations originate in vivo and
are intrinsically infectious. Once isolated, aggregates of the
rods behave as discrete infectious particles in cell culture. Elec-
tron tomography shows that PrP rods have a common
hierarchical structure which is very different to the individual,
long, non-infectious PrP fibres generated in vitro from recombi-
nant PrP. This distinctive three-dimensional structure now
provides a new basis for understanding prion infectivity and
the features that differentiate prions from non-infectious
protein assemblies. Determining the three-dimensional struc-
ture of the rods at a higher resolution is now clearly
required to establish the location of the N-linked glycans
which may be involved in linking the fibres. In this regard, bio-
logically relevant, high-affinity glycan : glycan interactions
have recently been reported [37]. Systematic generation of
prions from recombinant PrP remains an extremely challen-
ging research goal [31]. However with more detailed
knowledge of the rod structure, it may become possible to
engineer single recombinant PrP fibres into a paired assembly
to generate high-titre synthetic prions.
Presently, the mechanism of assembly of prions in vivo
remains to be determined. To date, we have been unable to
separate the individual fibres in the PrP rods by chemical
or physical means while still retaining infectivity. We have
also not observed single fibres in our purified preparations,strongly suggesting that the two fibres co-assemble during
prion formation. Clearly, if this is the case, the rods must
elongate in vivo and the presence of PrP rods of different
lengths in brain homogenate (together with variable associ-
ation with lipids) may underlie the wide distribution of
prion infectivity that is seen when brain homogenate is frac-
tionated in density gradients [5,7–9]. Resolving the structural
relationship between small-sized infectious particles in brain
homogenate with that of the larger infectious PrP rods that
we describe here remains an important goal, as the smaller
particles appear to account for a substantial proportion of
the total infectivity in brain homogenate [5–9]. On the basis
of this work, it seems highly likely that the small-sized infec-
tious particles in brain homogenate are simply truncated PrP
rods. Testing this hypothesis however remains highly chal-
lenging due to the difficulty of isolating homogeneous
preparations of the small-sized particles from brain.4. Material and methods
4.1. Research governance
Work with prion-infected samples was conducted in micro-
biological containment level 3 or level 2 facilities with strict
adherence to safety protocols.
4.2. Prion sources
In total, 10% (w/v) brainhomogenates from terminallyaffected
CD1mice propagating theRMLprion strain (I6200), from term-
inally affected C57Bl/6 mice propagating either the RML
(I14051) or ME7 (I14050) prion strain, or from terminally
affected Syrian hamsters propagating Sc237 prions (I9200)
were prepared as described previously [10]. Normal 10%
(w/v) brain homogenates from uninfected CD1 mice (I10340
or I14040) were used as control samples. Homogenates were
stored in aliquots at 2708C.
4.3. Prion purification
Comprehensive details of the purification method have been
described previously [10]. We used purified P4 fractions pre-
pared without PK digestion. The method produces a recovery
of approximately 10% of the prions present in the starting 10%
(w/v) brain homogenate so that resuspension of the purified
P4 pellet fraction in buffer at one-tenth of the volume of the
10% (w/v) brain homogenate from which it was derived pro-
duces prion preparations whose infectivity titre matches that of
the starting 10% (w/v) brain homogenate [10]. Subsequent con-
centrationof thepurifiedprions orbuffer exchangewas achieved
by centrifugation at 16 100g for 30 min and resuspension of the
pellet fraction into the desired volume and buffer of choice.
SDS-PAGE, silver staining and PrP immunoblotting (using
anti-PrP monoclonal antibody ICSM 35; D-Gen Ltd, London,
UK) was performed using established procedures [10,38].
4.4. Filtration experiments
Twenty-five microlitre aliquots of purified RML prions (prion
titre approx. 4 that of 10% (w/v) RML brain homogenate)
in 20 mM Tris, 150 mM NaCl pH 7.4 (TBS) containing 0.1%
(w/v) sarkosyl were thoroughly mixed with a pipette tip
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9and then sonicated briefly in a Sonicator 3000 (Misonix) at
40 W at 48C for a total of 60 s (2 30 s intervals) to disrupt
large PrP aggregates. Twenty microlitre aliquots were
added to pre-wetted 0.1 mm Ultrafree-MC centrifugal PVDF
filter units (Millipore, Cat # UFC30VV25) and centrifuged
at 12 000g for 30 s. The filtrate was isolated and the retentate
resuspended in 20 ml of TBS buffer containing 0.1% (w/v)
sarkosyl. Samples (including the sonicated starting material)
were analysed in the Scrapie Cell Assay (SCA) and by EM.
4.5. Standard Scrapie Cell Assay
Prion samples were diluted appropriately (typically either
1 : 1000 or 1 : 10 000) in OptiMEM or MEM (Invitrogen) and
infectivity quantified in the SCA using PK1/11 cells for
RML prions or LD9 cells for ME7 prions as previously
described [10,12]. After exposing the cells to prion samples
for 3 days, cells were split 1 : 8 into fresh cell culture media
and grown back to confluence. Two additional 3 day splits
were performed before transferring cells to ELISPOT (Multi
Screen Immobilon-P, Millipore, UK) plates to quantify the
number of cells containing PK-resistant PrP (spot numbers).
The SCA was calibrated by concomitant analyses of a
reference 10% (w/v) RML brain homogenate of known intra-
cerebral mouse LD50 prion titre (I6200; prion titre of 107.3+0.5
(mean+ s.d.) intracerebral LD50 units ml21) determined
from six endpoint titrations in Tg20 mice [10]. All infectivity
data (spot numbers) were correlated with the reference RML
brain homogenate and infectivity expressed as the equivalent
number of intracerebral mouse LD50 units present in the
purified prion samples.
4.6. Measuring prion infectivity in successive water
washes of electron microscopy grids
Two microlitres of purified RML prions (prion titre approx.
1 that of 10% (w/v) RML brain homogenate) were loaded
onto three separate glow-discharged 300 mesh carbon-
coated gold grids (Agar Scientific Ltd, Cat # S160A3) and
left to dry completely. The grids were then drawn succes-
sively through two 20 ml drops of water after which any
excess water on the grid was removed with a pipette tip
and pooled with the second water drop. In total, 2.5 ml ali-
quots were withdrawn from each of the water drops and
diluted into OptiMEM tissue culture media and tested for
their infectivity using the Scrapie Cell Assay. The infectivity
titre of 2 ml aliquots of the purified RML prion sample used
to load the grids was concomitantly determined, enabling
the infectivity in the water washes to be expressed as a per-
centage of that applied to the grids. Three grids loaded
with uninfected 10% (w/v) CD1 brain homogenate were per-
formed in parallel as a negative control. All grids from these
experiments were also visualized by negative stain EM to
confirm that PrP rods were bound to carbon and that the
carbon remained intact and was still attached to the grids.
Any grids from which carbon had detached were not
included in infectivity analyses.
4.7. Scrapie Cell Grid Assay
To measure the infectivity of samples bound to EM grids, 3 ml
of purified prions (prion titres ranging from 0.01 to 1 thatof 10% (w/v) RML brain homogenate) were loaded onto
three separate glow-discharged 300 mesh carbon coated
gold grids (Agar Scientific Ltd, Cat # S160A3) and left to
dry completely. Grids were transferred into a 20 ml drop of
cell culture medium inside a 24-well tissue culture plate
and 2 ml of PK1/11 cell suspension at 50 cells ml21 in
OFCS (OptiMEM, 10% FCS, penicillin and streptomycin)
added to the grids so that a total of 100 000 cells were
added per well. Cells were incubated for 3 days then har-
vested by washing the grid surface twice with 2  100 ml of
OFCS medium and transferred to a clean 24-well plate. All
200 ml washes from three identical replicate grids were
pooled (600 ml total volume), cells adjusted to a density of
16 cells ml21 with OFCS media, then 4000 cells per well
(250 ml) transferred to a new 96-well plate. After 4 days incu-
bation, cells were resuspended then split at a 1 : 8 dilution
into fresh OFCS media and passaged in a standard Scrapie
Cell Assay format, in which the cells were grown to conflu-
ence and split 1 : 8 three times before transferring samples
of the cells to ELISPOT plates for analysis of the number of
cells containing PK-resistant PrP. Infectivity of prion-
containing samples was calculated by correlation with a
serial dilution of 10% (w/v) brain homogenate of known
infectious titre and expressed in LD50 ml21. To determine
the efficiency with which the SCGA reported prion titre,
replicate aliquots of the purified prion samples were also con-
comitantly measured using the standard Scrapie Cell Assay
format (with samples diluted 1 : 10 000). In addition, 3 ml
replicate aliquots of the purified prion samples were added
to a 20 ml drop of media in a 24-well tissue culture plate
then 2 ml of PK1 cell suspension at 50 cells ml21 in OFCS
added. Cells were incubated for 3 days, after which each con-
fluent well was resuspended, the cells adjusted to a density of
16 cells ml21 with OFCS media and 4000 cells per well
(250 ml) transferred to a new 96-well plate. Thereafter, cells
were processed identically to those harvested from EM
grids. Uninfected CD1 brain homogenate was examined in
parallel in all the infectivity assay formats to act as a negative
control.4.8. Visualizing prion protein rods in crude brain
homogenate using detergent
Our experience with purified RML prion samples showed
that application of greater than or equal to 105 intracerebral
LD50 units to EM grids is required in order to readily visual-
ize PrP rods. Experiments with brain homogenate were
therefore designed with this knowledge. Fifteen microlitres
of 10% (w/v) RML brain homogenate was diluted twofold
or 100-fold with 2% (w/v) sarkosyl (prepared in D-PBS)
and incubated at room temperature for various time periods
between 2.5 and 60 min, after which the samples were centri-
fuged at 16 100g for 5 min. Supernatants were discarded and
the pellets resuspended in 4 ml of TBS buffer then immedi-
ately loaded onto EM grids and subsequently visualized by
negative stain EM. Further time course experiments were
performed in the presence of PK (Merck, Cat # 70663) at
200 mg ml21 from the time of addition of detergent to the
brain homogenate. PK activity was inhibited prior to centrifu-
gation of the sample by the addition of 4-(2-aminoethyl)-
benzene sulfonyl fluoride (AEBSF; Melford, Cat # T2147) to
1 mM final concentration.
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104.9. Isolation of prion protein rods from brain
homogenate in the absence of detergent
Two hundred microlitres of D-PBS plus 0.8 ml of Benzonase
(25 U ml21) were added to 200 ml of 10% (w/v) RML brain
homogenate, mixed thoroughly and then incubated at 378C
for 30 min with gentle agitation. Optiprep was added to a
final concentration of 35% (v/v) and mixed thoroughly,
after which the sample was centrifuged at 16 100g for
90 min at 378C. The lipid surface layer was removed and
retained. Forty microlitre aliquots of this fraction were
mixed with 160 ml of methanol and incubated for 1 h at
258C. Samples were then centrifuged at 16 100g for 30 min
and the pellets resuspended in 5 ml of water, after which
3 ml was loaded onto EM grids. Samples produced by this
method have a heterogeneous background when visualized
by EM. Much of the imaged surface is obscured by micellar
structures and extensive examination of the grids is required
to find PrP rods.
4.10. Heat denaturation of prions in brain homogenate
and purified samples
Ten microlitres of purified RML prions (prion titre approx.
1 that of 10% RML brain homogenate) in TBS buffer
containing 0.1% (w/v) sarkosyl were transferred to Protein
LoBind tubes and incubated at 25, 50, 75 and 1008C for 10,
30 or 60 min with gentle agitation. In parallel, 10 ml aliquots
of 10% (w/v) prion-infected brain homogenates (in D-PBS)
were incubated under the same conditions. At the defined
time points, samples were pulse centrifuged to recover the
sample to the bottom of the tube and immediately frozen
on dry ice. Aliquots of each sample were analysed for infec-
tivity in the Scrapie Cell Assay and examined by EM. For
analysis by EM, 2.5 ml of the samples were loaded onto EM
grids. To assess the relative PK sensitivity of the material
incubated at different temperatures, aliquots of the brain
homogenate or purified prion samples were digested with
final concentrations of 50 or 10 mg ml21 PK, respectively,
for 1 h at 378C. Digestion was terminated by the addition of
AEBSF to a final concentration of 1 mM after which samples
were immediately processed for PrP immunoblotting.
4.11. Guanidine hydrochloride denaturation of prions
in brain homogenate and purified samples
Ten microlitre aliquots of purified RML prions (prion titre
approx. 2.5 that of 10% RML brain homogenate) or aliquots
of 10% (w/v) RML brain homogenate (in D-PBS) were
dispensed into Protein LoBind tubes (Eppendorf) and centri-
fuged at 16 100g for 30 min (or 10 min for homogenate). The
supernatants were removed and the pellets resuspended in
20 mM Tris buffer pH 7.4 containing 0.1% (w/v) sarkosyl
and either 0, 0.5 or 1.0 M GuHCl (Sigma-Aldrich, Cat #
G3272) in a final volume of 10 ml. In addition, replicate con-
trols were set up in parallel using 20 mM Tris buffer pH 7.4
containing 0, 0.5 and 1 M NaCl. Following gentle agitation
at 258C for 30 min, reactions were stopped by freezing the
samples on dry ice. Aliquots of each sample were analysed
for infectivity in the Scrapie Cell Assay, examined by EM or
processed for PrP immunoblotting before or after digestionwith PK as described above for heat treated samples. For
infectivity measurement in the Scrapie Cell Assay, samples
were diluted either 1 : 1000 or 1 : 10 000 in tissue culture
medium so that the final concentration of GuHCl was
below 1 mM to prevent toxicity to the cells.
4.12. Sonication and ultracentrifugation of purified
prions
One hundred microlitres of purified RML prions (prion titre
approx. 1 that of 10% RML brain homogenate) were trans-
ferred to a Sonicator 3000 (Misonix) at 48C. Samples were
sonicated at 40 W for a total of 10 min using 30 s bursts
with 60 s intervals between bursts then pulse centrifuged to
recover the sample to the bottom of the tube. Concomitantly,
identical 100 ml aliquots of the purified RML prions were cen-
trifuged at 100 000g maximum in a TLA-110 rotor for 60 min
using an Optima MAX-XP ultracentrifuge (Beckman Coulter)
at 258C. Resulting pellet fractions were gently resuspended
back into the supernatant (within the same tube) using a
pipette tip. Sonicated or centrifuged samples together with
replicate aliquots of the untreated purified RML prions
were analysed by EM, in the Scrapie Cell Assay and by PrP
immunoblotting or ELISA [10] to determine the PrP content
of the samples.
4.13. Growth of recombinant prion protein fibrils
Recombinant mouse PrP (Prnp allele a; amino acid residues
91–231) was converted into a b-sheet conformation [32,39]
by incubation in 10 mM sodium acetate/10 mM tris-acetate
buffer pH 8.0 containing 100 mM dithiothreitol (DTT) and
6 M GuHCl for 16 h, followed by dialysis in 10 mM sodium
acetate/10 mM tris-acetate buffer pH 4 containing 1 mM
DTT. Insoluble material was removed by centrifugation at
150 000g for 4 h. The supernatant was concentrated using
Vivaspin 20 centrifugal concentrators. Subsequently, samples
were adjusted with 10 mM sodium acetate/10 mM tris-
acetate buffer pH 3.0 to give a final protein concentration of
1.2 mg ml21, after which 100 ml aliquots were incubated for
three to five months without agitation at 258C in sealed
1.5 ml tubes as described previously [32]. Fibrils were
harvested by centrifugation of the solutions at 13 000g for
45 min then pellets resuspended in 10 mM sodium acetate/
10 mM tris-acetate buffer pH 3.0–50% of the original
volume. To disrupt recombinant PrP fibrils (when required),
samples were sonicated at 40 W in a Sonicator 3000 (Misonix)
at 48C for a total of 10 min using 30 s bursts with 60 s inter-
vals between bursts. Samples were then either diluted 1 in
5 in 10 mM sodium acetate/10 mM tris-acetate buffer pH
3.0 and loaded onto EM grids or analysed for infectivity
using the Scrapie Cell Assay.
4.14. Negative stain electron microscopy
Samples were loaded on EM grids within a class 1 microbio-
logical safety cabinet in a microbiological containment level 3
laboratory. Three microlitres of purified prions (prion titre
typically approx. 2.5 that of 10% RML brain homogenate)
or recombinant PrP fibrils (diluted 1/5, approx. 0.5 mg ml21)
were loaded onto 300 mesh 3.05 mm carbon-coated copper
grids (Electron Microscopy Sciences, Cat # CF300-Cu) that
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11had been glow discharged for 40 s using an EMS 100 glow
discharge unit (Electron Microscopy Sciences, USA). Typi-
cally, samples were adsorbed to the grid surface for 2 min
after which excess solution was removed by blotting with
grade 4 Whatman paper. Grids were then washed briefly
by passing through two water drops then stained with 2%
(w/v) uranyl acetate for 45 s, blotted and air dried. In some
cases samples were completely dried on to the grids, in
which case water washes were omitted and the grids then
stained with uranyl acetate, blotted and air dried. Grids
loaded with infectious samples were inserted into the micro-
scope using a dedicated sample holder for mouse prions with
strict adherence to risk assessment and microbiological con-
tainment level 2 safe working practice. Images were
acquired on an FEI Tecnai T10 electron microscope (FEI,
Eindhoven, NL) operating at 100 kV and recorded on a
1 k  1 k charged couple device (CCD) camera (Gatan) at a
nominal magnification of 44 000 with a pixel size of 3.96 A˚.
4.15. Immunogold labelling of purified prions or prion
protein rods in crude brain homogenate
Purified prion rods isolated from the equivalent of 0.5 ml of
10% (w/v) RML brain homogenate were labelled with anti-
PrP monoclonal antibody SAF-32 (Bioquote Ltd, Cat #
189720) and goat anti-mouse IgG conjugated to 10 nm gold
particles (Sigma-Aldrich, Cat # G7652) as described pre-
viously [10]. To label PrP rods in crude brain homogenate,
an equal volume of 4% (w/v) sarkosyl was added to 100 ml
10% (w/v) RML brain homogenate followed by incubation at
378C for 30 min. The sample was then centrifuged at 16 100g
for 30 min. Pellets were resuspended in 100 ml of TBS contain-
ing 5% (v/v) glycerol and 0.1% (w/v) sarkosyl and passed
through a 0.65 mm Ultrafree-MC Centrifugal PVDF filter
unit (Millipore, Cat # UFC40DV25) to remove collagen
fibres and intermediate filaments. Labelling of the filtrate
fraction was then performed as described for purified prion
samples [10].
4.16. Electron tomography
Samples were loaded onto glow-discharged 200 mesh
carbon-coated copper finder grids (Electron Microscopy
Sciences, Cat # CFLF200-Cu) and stained as described for
negative stain EM. Single- and dual-axis tilt series were
acquired using a dual-axis tomography holder (FischioneInstruments) on a Tecnai 12 electron microscope (FEI, Eind-
hoven, NL) operating at 120 kV. SerialEM [40] was used to
collect the tilt series using a tilt range of –708 to þ708 with
28 increments. Digital images were recorded on a 1 K Gatan
Multiscan 794 CCD camera at a nominal magnification of
42 000 with a pixel size of 4.1 A˚ and a typical defocus of
0.7 mm. Volumes for 17 recombinant PrP fibrils were
analysed from four tomograms (reconstructed from 2
single- and 2 dual-axis tilt series), volumes for 28 ex vivo
PrP rods purified from RML-infected CD1 brain were ana-
lysed from eight tomograms (reconstructed from 3 single-
and 5 dual-axis tilt series), volumes for 21 ex vivo PrP rods
from ME7-infected C57Bl/6 brain were analysed from
seven tomograms (reconstructed from 2 single- and 5 dual-
axis tilt series), and volumes for 24 ex vivo PrP rods from
RML-infected C57Bl/6 brain were analysed from four tomo-
grams (reconstructed from 3 single- and 1 dual-axis tilt
series). After use, the holder was decontaminated by
plasma cleaning for 15 min (Fischione Instruments). Tomo-
grams were reconstructed from the tilt series with IMOD
v. 4.3 [41], using local patch tracking for alignment. The
isosurface view (figure 5e) was rendered after Gaussian
low-pass filtering and removal of isolated noise densities in
CHIMERA (http://www.cgl.ucsf.edu/chimera/).
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